Current therapies for patients with HF with preserved ejection fraction are limited and no drugs have proven effective yet. A meta-analysis-based study with limited data of VERTIS CV and DECLARE-TMI 58 trials has suggested some effects of SGLT2 inhibitors on HF hospitalizations in HF with preserved ejection fraction [21]. Here, SLC5A2 is linked to hydrops fetalis.